Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

doi:10.3350/cmh.2024.0116

Editorial

. 2024 Apr;30(2):150-153.

doi: 10.3350/cmh.2024.0116. Epub 2024 Feb 22.

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh¹, Naomy Kim², Ju Dong Yang^{2

3

4}

Affiliations

¹ Middle East Liver Diseases Center, Tehran, Iran.
² Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³ Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁴ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

PMID: 38385196
PMCID: PMC11016470
DOI: 10.3350/cmh.2024.0116

Editorial

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh et al. Clin Mol Hepatol. 2024 Apr.

. 2024 Apr;30(2):150-153.

doi: 10.3350/cmh.2024.0116. Epub 2024 Feb 22.

Authors

Mohammad Saeid Rezaee-Zavareh¹, Naomy Kim², Ju Dong Yang^{2

3

4}

Affiliations

¹ Middle East Liver Diseases Center, Tehran, Iran.
² Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
³ Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
⁴ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

PMID: 38385196
PMCID: PMC11016470
DOI: 10.3350/cmh.2024.0116

No abstract available

Keywords: Complement system proteins; Drug repositioning; Hepatocellular carcinoma; Liver diseases; Mendelian randomization.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

J.D.Y. provides a consulting service for AstraZeneca, Eisai, Exact Sciences, Exelixis, Fujifilm Medical Sciences, and Gilead Sciences. M.S.R-Z. and N.K. declare no conflict of interest.

Comment on

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.
Shi Y, Dong H, Sun S, Wu X, Fang J, Zhao J, Han J, Li Z, Wu H, Liu L, Wu W, Tian Y, Yuan G, Fan X, Xu C. Shi Y, et al. Clin Mol Hepatol. 2024 Jan;30(1):80-97. doi: 10.3350/cmh.2023.0343. Epub 2023 Dec 7. Clin Mol Hepatol. 2024. PMID: 38061333 Free PMC article.

Cited by

Reassessing the Impact of Coffee Consumption on Liver Disease: Insights from a Large-Scale Cohort Study with IPTW Adjustment.
Yang K, Chang Y, Jeong SW, Jang JY, Ryu T. Yang K, et al. Nutrients. 2024 Jun 26;16(13):2020. doi: 10.3390/nu16132020. Nutrients. 2024. PMID: 38999772 Free PMC article.
Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting.
Yang K, Chung BS, Ryu T. Yang K, et al. Nutrients. 2024 Aug 2;16(15):2532. doi: 10.3390/nu16152532. Nutrients. 2024. PMID: 39125411 Free PMC article.
Reply to correspondence on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets".
Rezaee-Zavareh MS, Kim N, Yang JD. Rezaee-Zavareh MS, et al. Clin Mol Hepatol. 2024 Oct;30(4):1037-1038. doi: 10.3350/cmh.2024.0320. Epub 2024 May 2. Clin Mol Hepatol. 2024. PMID: 38697652 Free PMC article. No abstract available.
Causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomisation study.
Tang J, Zhang S, Jiang L, Liu J, Xu J, Jiang C, Chen Z, Zhou X, Fuller C, Huang J, Chen H, Yang G, Bai C, Yin D, Li B, Chi H. Tang J, et al. J Cancer. 2024 Jun 3;15(13):4219-4231. doi: 10.7150/jca.96744. eCollection 2024. J Cancer. 2024. PMID: 38947379 Free PMC article.
Correspondence to editorial on "Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets".
Shi Y, Yuan G, Fan X, Xu C. Shi Y, et al. Clin Mol Hepatol. 2024 Oct;30(4):987-988. doi: 10.3350/cmh.2024.0266. Epub 2024 Apr 19. Clin Mol Hepatol. 2024. PMID: 38637982 Free PMC article. No abstract available.

References

1. Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–1991. - PubMed
1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–1347. - PMC - PubMed
1. Rehm J, Shield KD. Global burden of alcohol use disorders and alcohol liver disease. Biomedicines. 2019;7:99. - PMC - PubMed
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
1. Shin E, Schwarz KB, Jones-Brando LV, Florea LD, Sabunciyan S, Wood LD, et al. Expression of HLA and autoimmune pathway genes in liver biopsies of young subjects with autoimmune hepatitis type 1. J Pediatr Gastroenterol Nutr. 2022;75:269–275. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–1991. - PubMed

[2] Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978–1991. - PubMed

[3] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–1347. - PMC - PubMed

[4] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77:1335–1347. - PMC - PubMed

[5] Rehm J, Shield KD. Global burden of alcohol use disorders and alcohol liver disease. Biomedicines. 2019;7:99. - PMC - PubMed

[6] Rehm J, Shield KD. Global burden of alcohol use disorders and alcohol liver disease. Biomedicines. 2019;7:99. - PMC - PubMed

[7] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed

[8] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed

[9] Shin E, Schwarz KB, Jones-Brando LV, Florea LD, Sabunciyan S, Wood LD, et al. Expression of HLA and autoimmune pathway genes in liver biopsies of young subjects with autoimmune hepatitis type 1. J Pediatr Gastroenterol Nutr. 2022;75:269–275. - PMC - PubMed

[10] Shin E, Schwarz KB, Jones-Brando LV, Florea LD, Sabunciyan S, Wood LD, et al. Expression of HLA and autoimmune pathway genes in liver biopsies of young subjects with autoimmune hepatitis type 1. J Pediatr Gastroenterol Nutr. 2022;75:269–275. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Affiliations

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical